

# PRESCRIBING GUIDANCE PRESCRIBING CANNABIS MEDICINES FOR MANAGEMENT OF ANOREXIA-CACHEXIA IN PATIENTS WITH ADVANCED CANCER

## About this document

This Prescribing Guidance has been developed to provide practical interim information to assist NSW medical practitioners in their decision-making around prescribing, managing and monitoring the use of cannabis medicines for the management of anorexia-cachexia in patients with advanced cancer. The Prescribing Guidance:

- Provides a summary of standard, registered therapeutic options in the management of anorexia-cachexia, which are used prior to considering the use of cannabis medicines.
- Details important considerations for prescribing cannabis medicines, including precautions and adverse events, drug interactions, dosing and monitoring outcomes.
- Presents information on delta-9-tetrahydrocannabinol (THC)-based cannabis medicines, as information on the use of other medicinal cannabinoids (other than THC) cannot be provided at this stage due to very limited evidence in the literature.
- Draws on the Therapeutic Goods Administration (TGA) guidance documents and, as such, requires medical practitioners to review the TGA's guidance before making a decision to prescribe cannabis medicine products.

## Key points

- The TGA's Guidance for the use of medicinal cannabis in the treatment of palliative care patients in Australia<sup>1</sup> has identified little evidence for symptom benefit from cannabinoid medicines in palliative care patients with anorexia-cachexia syndrome.
- All registered therapeutic options are exhausted or deemed inappropriate (due to adverse effects or contraindications) prior to the consideration of a cannabis medicine for anorexia-cachexia syndrome.
- Medical practitioners should review the guidance advice made available by the TGA before making a decision to prescribe cannabis medicine products for anorexia-cachexia syndrome.
- NSW-based medical practitioners can obtain further information and assistance with prescribing tailored to the patient-specific clinical context from the NSW Cannabis

Medicines Advisory Service. The service can be contacted via email [HNELHD-CMAS@health.nsw.gov.au](mailto:HNELHD-CMAS@health.nsw.gov.au).

## Current clinical trials

Clinical trials related to anorexia-cachexia that are currently recruiting can be located via searching the Australian New Zealand Clinical Trials Registry.

## Use of evidence-based therapies for anorexia-cachexia syndrome

Evidence-based management options in accordance with clinical practice guidelines, where available, must be offered to patients experiencing anorexia-cachexia syndrome in advanced cancer prior to considering use of cannabis medicines.

CareSearch<sup>2</sup> – the Palliative Care Knowledge Network – has resources available to assist doctors and provides evidence-based care for patients with appetite problems and anorexia-cachexia syndrome.

The eTG complete<sup>3</sup>, particularly 'Gastrointestinal Symptoms in Palliative Care', is another useful resource, (available through [www.ciap.health.nsw.gov.au](http://www.ciap.health.nsw.gov.au) for NSW Health employees).

## Summary of best practice in management of anorexia-cachexia syndrome in patients with advanced cancer


The following information is derived from practice guidelines including CareSearch<sup>2</sup>, eTG complete<sup>3</sup> and the American Society of Clinical Oncology (ASCO) guidelines<sup>4</sup>.

Anorexia (lack of appetite) and weakness and wasting (cachexia) are among the most recognised and troubling symptoms for patients with cancer, their families and carers<sup>3</sup>. Common and potentially reversible contributors to anorexia include oral thrush/mucositis, dysgeusia, dysphagia, constipation, depression, dyspnoea and medication side effects<sup>2</sup>.

## Management of anorexia-cachexia syndrome in advanced cancer

- Routine measurement of weight is not helpful and may contribute to patient and carer anxiety.
- Family, social and cultural expectations can be supported through compassionate discussion of expectations and outcomes.
- The history and examination should be retaken to reveal new, potentially treatable factors.
- Consider non-pharmacological options including provision of small food portions, a switch to a focus on enjoyment of food rather than nutritional benefit, and focus on patient preference.
- Oral care should be provided and treatment initiated for oral thrush or mucositis (where present).
- Nausea, constipation and pain should be managed according to best evidence.
- Dysphagia should be investigated if appropriate. If a patient who has dysphagia wants to eat, consider referral to a dietician and/or speech pathologist.
- Where depression is a contributing factor, consider whether a trial of an antidepressant is indicated. Different antidepressants and anxiolytics have benefits on different aspects of weight, food enjoyment and satiety.
- If slow gastric emptying is contributing to early satiety, commence metoclopramide or domperidone unless contraindicated.
- Oral nutritional supplements may reduce weight loss and improve quality of life but have not been shown to affect mortality<sup>4</sup>.

### Best Practice Guidance for Management of Anorexia and Cachexia in Palliative Care Patients with Advanced Cancer



- There is evidence that megestrol acetate improves appetite in advanced cancer but has not been shown to improve quality of life<sup>5</sup>. Megestrol acetate adverse events include oedema, thromboembolic phenomena and death.
- There is evidence that corticosteroids such as prednisolone and dexamethasone improve appetite in advanced cancer. Some studies have suggested improved quality of life with corticosteroids<sup>5</sup>. Careful consideration should be made to the harm vs. benefit profile and addition of a proton pump inhibitor, which also has side effects. If loss of appetite is causing an impact on patient quality of life, a short-term (less than 14 days) trial of 2-4 mg daily dexamethasone may be beneficial. If there is no improvement after 5 days of treatment, cease therapy.

## Prescribing cannabis medicines for the management of cachexia/anorexia syndrome in patients with advanced cancer

If the decision to proceed to cannabis medicine prescription is made, consider the information below.

### The prescriber

The prescriber should have a key involvement in provision of care, including the patient's palliative care physician, an oncologist or a general practitioner in liaison with a specialist practitioner, and an ongoing relationship in the patient's journey. All members of the treating team should be aware of the decision to prescribe a cannabis medicine and documented in the patient's record. This enables awareness of adverse events and drug interactions early. Follow up and assessment of efficacy and toxicity is essential.

Given the current status of most cannabis medicines as unregistered medicines, prescribers should consider seeking advice from their medical indemnity insurers prior to prescribing.

### The patient

The patient must give informed consent to treatment. The consent process should include:

- Most available cannabis medicines are unregistered and non-reimbursed (see products available for exceptions).
- The true likelihood efficacy and side effects of this therapy are still being researched, but possible effects and side effects of treatment should be discussed.
- There will be restrictions on driving and operating heavy machinery.
- The patient should also be given clear information about therapeutic goals and likely stopping criteria.
- Potential for dependence or withdrawal.

***Patients should be advised that they are not able to drive while treated with cannabis medicines.***

Patients should be informed that measurable concentrations of THC can be detected in saliva for significant periods of time after administration. Further information is available from the [Transport for NSW Centre for Road Safety](#)<sup>6</sup> and in NSW Health's [Prescribed Cannabis Medicines and Fitness to Drive Factsheet](#)<sup>7</sup>.

## Prescribing a cannabis medicine: important considerations

The following has been adapted from the TGA's [Guidance for the use of medicinal cannabis in Australia: Patient information](#)<sup>8</sup>

## Cannabis products

- A variety of products are available.
- There are up to 100 cannabinoids (chemical compounds) in the cannabis plant, many are active.
- Many of the studies described in the medical literature have used either smoked cannabis (which is not recommended on health grounds) or purified cannabidiol (CBD) or synthetic THC cannabis medicines.
- THC is responsible for the psychoactive effects of cannabis and is the reason cannabis is used recreationally. THC may contribute to reduction of nausea, vomiting, pain and muscle spasms as well as improvements in sleep and appetite.
- CBD has effects on neurological function including seizure activity, sedation, and dizziness, however psychosis has not been reported. It may be useful in the management of seizures, and may have anxiolytic and antipsychotic effects for some people.
- Adding CBD to a THC product in a patient with toxicity to reduce toxicity is unproven and may increase the THC exposure. It is more appropriate to reduce the dose and/or frequency of THC.
- Different cannabis products contain different ratios of THC to CBD.
- There are other cannabinoids under research including cannabigerol (CBG), tetrahydrocannabivarin (THCV), cannabinol (CBN) and cannabichromene (CBC).

## Route of administration

### Vaporising

- Rapid onset of action, usually within minutes.
- High blood concentrations of cannabinoids with shorter duration of effect than oral.
- Peak concentration in 30 minutes, effects last 2-4 hours.
- Useful for symptoms requiring rapid and intermittent relief.

### Oral/oro-mucosal/oro-buccal administration

- Care with dosing with oral liquid.
- Slow onset of action with first effects at 30-90 minutes, peak effect at 2-4 hours.
- Effects can last 8-24 hours.
- Useful for symptoms requiring relief over longer periods of time (similar to controlled release medications).
- Titration of dosing may be easier with oro-mucosal sprays than oral formulations.
- Sprays may be easier for those with difficulty swallowing.

### Topical

- Cannabinoids are highly lipophilic compounds and this may facilitate permeation into the skin. However, the degree of water solubility (or polarity) of these compounds will also influence the rate and extent of transfer across the skin.
- THC is relatively less well absorbed than CBD and CBN.
- Time of onset, duration of action and likelihood of depot occurrence are unknown although it is expected the time of onset will be slower than vaporised route and faster than oral. This route is therefore not recommended at this stage.

## Products available

There are currently two registered cannabis medicines in Australia:

- Sativex® oro-mucosal spray (for the indication of moderate to severe spasticity in patients with multiple sclerosis)

- Epidyolex® (CBD 100 mg/mL) oral liquid (for the indication of epilepsy, as an adjunctive therapy for Lennox-Gastaut, or Dravet syndrome associated seizures in patients ≥ 2 years of age).

It is noted that some cannabinoids have different scheduling than others, with CBD available as Schedule 3 as soon as a registered product is available.

The U.S. Food and Drug Administration have approved the use of synthetic cannabinoid products, for specified indications, including:

- Marinol®<sup>11</sup> and Syndros®<sup>12</sup> - dronabinol\* (anorexia in patients with Acquired Immune Deficiency Syndrome (AIDS) who have lost weight and treatment refractory or cancer chemotherapy associated nausea and vomiting)
- Cesamet®<sup>13</sup> - nabilone\* (treatment refractory, cancer chemotherapy associated nausea and vomiting).

The cannabinoid composition of unregistered products can be generally grouped into THC-predominant, CBD-predominant, THC and CBD ~1:1 and other cannabinoids and ratios.

A variety of unregistered cannabis medicines (that conform to the requirements of the Therapeutic Goods (Standard for Medicinal Cannabis) (TGO93) Order and the Therapeutic Goods (Microbiological Standards for Medicines) (TGO 100) Order are available, including chewable tablets, crystals, flos/granulate for inhalation, lozenges, oral oils, oral solutions, oro-mucosal sprays, oral capsules, sublingual wafers, tinctures, topical balm, and transdermal patch dosage forms.

\*Some cannabis products and dose forms may not be readily

December 2017 (see Table 1). Further information updates were obtained from a literature review in MEDLINE and Embase from January 2018 to December 2020. However, dosing and other Product Information was not included, therefore this guidance can be used in combination with that information.

In summary, the most relevant clinical data to date includes a 2018 meta-analysis of cannabis medicines in advanced cancer which demonstrates no significant improvement in anorexia, weight loss or total energy intake<sup>14</sup>, and a single, low quality study, suggesting that megestrol acetate is superior to dronabinol for improving appetite and health related quality of life. There was no benefit from using dronabinol in combination with megestrol acetate in this study<sup>15</sup>.

A small randomised controlled trial in 2018 examined the effect of nabilone on caloric intake and quality of life in patients with advanced non-small cell lung cancer. This study showed an increase in carbohydrate intake and improvement in limited components of health-related quality of life. There was no difference in self-reported appetite or weight loss<sup>16</sup>.

The current evidence in relation to cannabis medicine product use in patients with advanced cancer indicates no clear benefit in comparison to placebo regarding the end points of appetite or weight loss<sup>17</sup>. Therefore, cannabis medicine products should only be trialled in palliative care whereby standard treatments have been trialled and failed<sup>1</sup>, with full disclosure of the potential lack of efficacy and toxicity, and likelihood of drug interactions with registered palliative care products.

Overall, given the low number and quality of studies regarding the use of cannabis medicine products in managing anorexia-cachexia in advanced cancer, it is recommended that patients

**Table 1 Extract from Symptom Control in Cancer,**

In Guidance for the use of medicinal cannabis in the treatment of palliative care patients in Australia<sup>1</sup>

Evidence Grade	Cannabinoid used	Outcomes
C - Unclear scientific evidence for this use	Dronabinol, THC:CBD, THC	There was a non-significant effect of medicinal cannabis to reduce cancer pain.
D - Fair scientific evidence against this use (it may not work)	Dronabinol, THC:CBD, THC	There were no significant differences between medicinal cannabis and placebo in effects on patients' weight, caloric intake, appetite, nausea and vomiting, sleep, depressed mood, or quality of life. There were also no significant differences between medicinal cannabis and placebo in development of cognitive impairment or dizziness during treatment.
C - Unclear scientific evidence for this use	Cannabis sativa	All cancer and anti-cancer treatment symptoms (e.g. nausea, vomiting, mood disorders, fatigue, weight loss) were improved after initiating cannabis therapy. The lack of controlled studies restricts the conclusiveness of this finding and the clinical relevance is also unknown.
C - Unclear scientific evidence for this use	Dronabinol	Patients receiving dronabinol reported an increase in appetite and a decrease in nausea, however the treatment effects decreased as the disease progressed. The lack of controlled studies restricts the conclusiveness of this finding.
C - Unclear scientific evidence for this use	Nabilone	Patients receiving nabilone reported decreases in pain scores, morphine use, nausea, anxiety, overall distress, and borderline significant improvement in appetite. The lack of controlled studies restricts the conclusiveness of this finding.

available onshore in Australia. Some synthetic cannabis medicine products that are available overseas may require importation and necessary permits via the Special Access Scheme.

## Evidence for use

The following has been developed and adapted from the Guidance for the use of medicinal cannabis in the treatment of palliative care patients in Australia<sup>1</sup> published by the TGA in

are encouraged to enrol in available clinical trials of cannabinoids in palliative care<sup>1</sup>.

## Precautions

The following has been adapted from the TGA's Guidance for the use of medicinal cannabis in Australia: Overview<sup>18</sup>.

Cannabis medicine products containing THC are generally not appropriate for patients who:



- Have a previous psychotic or concurrent active mood or anxiety disorder.
- Are pregnant, planning on becoming pregnant, or breastfeeding.
- Have unstable cardiovascular disease.

Any allergies to potential carrier oils (e.g. sesame, canola, sunflower) should be noted as products available in Australia often contain oils. This may influence product selection.

Consider concomitant medication use and potential for pharmacokinetic and pharmacodynamic drug interactions (see below).

## Adverse effects

The following has been adapted from the TGA's [Guidance for the use of medicinal cannabis in the treatment of palliative care patients in Australia](#)<sup>1</sup>. It is noted that this guidance is specifically for anorexia and cachexia in this setting.

**Adverse events such as confusion, pain, diarrhoea or hallucinations may impact the overall aims of the palliative medicine and reduce quality of life, both directly and via drug interactions, and therapeutic use should thus be evaluated on a case-by-case basis.**

Serious adverse events (SAEs) such as psychosis and cognitive distortion requiring external assistance have been described clinically, but the severity, time course and further details are not recorded. SAEs are also likely where metabolism of THC or CBD or concomitant prescribed medications may be affected by induction or inhibition of enzymes in the P450 system, or where there are similar pharmacodynamic effects.

Based on the available studies, commonly reported adverse events in the use of cannabis medicine products in the palliative care setting are detailed in Table 2 below. In a small (15 patient) study, 11 had anxiety symptoms.

The cessation of long-term (of more than several months) use of THC-based medicines may also be associated with the experience of discontinuation effects.

**Table 2 Commonly reported adverse events in the palliative care setting**  
Adapted from the TGA Guidance for the use of medicinal cannabis in the treatment of palliative care patients in Australia<sup>1</sup>

Symptom	Percentage of patients
nausea	21%
somnolence	20%
dizziness	16%
asthenia	13%
tiredness/fatigue	12%
vomiting	11%
anaemia	11%
confusion	10%
pain	10%
diarrhoea	8%
headache	8%
dyspnoea	8%
hallucinations	5%

## Drug interactions

While some cannabis medicines contain only one active ingredient, others contain THC and/or CBD in varying ratios as well as other cannabinoids or compounds extracted from cannabis plant material. The systemic exposure of the patient to the cannabinoids THC and CBD will be influenced by the

formulation, dose administered, route of administration and the frequency of administration.

Current information sources for drug interactions with cannabinoids are drug interaction databases, the Product Information on Epidyolex® (CBD)<sup>10</sup>, Cesamet® (nabilone)<sup>13</sup>, Marinol® (dronabinol)<sup>11</sup>, and Sativex®<sup>9</sup> (THC and CBD), recently published case reports, in-vitro studies and clinical trial outcomes in the primary literature.

As part of cannabinoid drug interaction assessment, patient variables that also need to be considered include but are not limited to polypharmacy, patient age, hepatic function, comorbidities and genetic polymorphisms. Diet (fed or fasted state, components of food) is a variable that can influence bioavailability of oral oils. Many of these factors are confounders in case reports in the published literature. Lack of formal causality analysis in many case reports also limits the interpretation of described outcomes.

## Pharmacokinetic drug-drug interactions

**Plasma THC and CBD concentrations may be increased or decreased when co-administered with medications that inhibit or induce enzymes involved in the metabolism of THC and CBD.**

### Enzyme Inhibition or Induction

The cytochrome P450 (CYP) enzymes CYP2C9 and CYP3A4 play a significant role in the metabolism of THC<sup>19</sup>. Pharmacogenetic data also supports CYP2C9 being a significant contributor to THC metabolism<sup>20</sup>.

CBD is primarily metabolised by CYP2C19 and also CYP3A4<sup>19</sup>. Other CYP enzymes including CYP1A1, CYP1A2, CYP2C9, CYP2D6 and CYP3A5 may also play a role in CBD metabolism<sup>21,22</sup>.

Induction or inhibition of these CYP enzymes may affect the pharmacokinetics of THC and CBD. Co-administration of ketoconazole (a strong CYP3A4 inhibitor) was observed to significantly increase plasma THC and CBD concentrations. Co-administration of rifampicin (a strong CYP3A4 and CYP2C19 inducer) resulted in decreased plasma THC and CBD concentrations. However, when omeprazole (a CYP2C19 inhibitor) was co-administered with THC, no changes in plasma THC concentration were observed<sup>23</sup>.

It is possible that other drugs which are inhibitors or inducers of the enzymes CYP3A4, CYP2C9 and CYP2C19 may affect the pharmacokinetics of THC and CBD. Care should be taken when prescribing such medications, during dose modifications or when discontinuing these medications in patients taking cannabinoids. For further information on drugs which are CYP inhibitors and inducers please refer to resources such as the Australian Medicines Handbook.

Cannabinoids are also subject to UDP-glucuronosyltransferase (UGT)-dependent glucuronidation by UGT enzymes. CBD undergoes direct conjugation by UGT enzymes while UGT enzymes play an important role in metabolism of THC metabolites THC-OH and THC-COOH<sup>19,24</sup>. CBD is a substrate of the UGT enzymes UGT1A7, UGT1A9, and UGT2B7. No formal drug-drug interaction studies with UGT inhibiting drugs have been reported. However, caution should be taken if CBD and

**THC and CBD may affect plasma drug concentrations of co-administered medications.**

drugs which inhibit UGT1A7, 1A9 and 2B7 enzymes are co-administered. Dose reduction may be required<sup>10</sup>.

In-vitro studies have also indicated that, besides being substrates of CYP enzymes, CBD and THC may also act as inhibitors of CYP enzymes.

A recent review compared in-vitro inhibition parameters to physiologically achievable cannabinoid concentrations and concluded that CYP2C9, CYP1A1/2, CYP1B1, CYP2D6, CYP2C19, CYP2B6 and CYP2J2 are likely to be inhibited by THC and CBD while CYP3A4/5/7 are potentially inhibited by CBD. However, it should be noted that contradictory in vitro results reporting both activation and inhibition of CYP2C9 have been reported<sup>25</sup>. Product Information for Epidyolex<sup>®</sup><sup>10</sup> suggests there may be inhibitory effect at clinically relevant concentrations on 2C8, 2C9, 2D6 and 2C19 and possible dual inhibition/induction effect for 1A2 and 2B6<sup>26</sup>.

CBD may also inhibit UGT1A9 and UGT2B7. An in-vitro study using ethanol as a substrate reported that CBD produced significant reduction of UGT1A9 and UGT2B7 activity. UGT enzymes are involved in glucuronidation of a range of drugs. Inhibition of these enzymes will reduce excretion of drugs that are substrates. However, the clinical relevance of any inhibition by cannabinoids has not been assessed. Since many commonly used medications undergo glucuronidation (including paracetamol, ibuprofen, tapentadol, canagliflozin, sorafenib, regorafenib, propofol, valproic acid, mycophenolate), CBD should be used with caution in patients who are stabilised on medications which undergo glucuronidation and when commencing these medications. Patients should be carefully monitored for side effects<sup>26</sup>.

In vitro studies have shown Sativex<sup>®</sup> has broad CYP450 enzyme inhibition effects. Although these effects may occur at concentrations higher than those observed with the registered dose of Sativex<sup>®</sup>, in practice many patients are using doses of other unregistered products that exceed the registered dose of Sativex<sup>®</sup>. Monitoring is recommended to detect possible clinical implications of elevated drug concentrations<sup>9</sup>.

In summary, caution should be exercised when considering prescribing cannabis products with medications that undergo significant metabolism by CYP2C19, CYP2C9 and CYP1A2 or by UGT enzymes due to the possibility of altered disposition<sup>25</sup>. Narrow therapeutic index (NTI) drugs which are metabolised by these enzymes should be closely monitored. While in-vitro and animal studies provide some preliminary information, well-designed clinical trials are needed to fully evaluate the clinical significance of enzyme induction and inhibition drug interactions. Route of administration, dose and duration of dosing may also influence whether significant interactions due to enzyme inhibition or induction occur.

Patients should also be informed of the possibility of drug-drug interactions when cannabinoids are co-administered with other medications, particularly with NTI drugs.

**Smoking cannabis may increase the clearance of medicines metabolised by the P450 system, particularly 1A1 and 1A2.**

CYP1A1 and CYP1A2 enzyme activity is increased by both cannabis and tobacco smoking and the induction effect between both tobacco and cannabis smoking is additive. Mechanism for induction of enzymes is thought to be due to the polycyclic aromatic hydrocarbons produced by pyrolysis. Dose adjustments for drugs metabolised by these enzymes may be required. Rapid downregulation of CYP1A enzymes occurs on smoking cessation and dose reduction of CYP1A metabolised drugs may

be necessary even in the first few days after smoking cessation<sup>27</sup>.

### **P-glycoprotein inhibition (P-gp)**

Drug efflux transporters, such as P-gp plays a significant role in absorption and clearance of some drugs. In vitro and animal studies have observed that CBD and THC interact with P-gp. An in-vitro study indicated that CBD may significantly inhibit P-gp mediated drug transport and influence absorption and disposition of other drugs which are P-gp substrates<sup>28</sup>. A study which administered the P-gp substrate risperidone and THC to mice demonstrated that THC exposure increased P-gp expression in various brain regions important to risperidone's antipsychotic action, reversing the neurobehavioural effects of risperidone. When clozapine (which is not a P-gp substrate) was co-administered with THC, the behavioural effects of clozapine were not affected<sup>29</sup>. However, not all in-vitro studies have demonstrated an effect of THC or CBD on P-gp<sup>25</sup>.

Further research is needed to confirm the clinical presence and relevance of transporter interactions. Until this research is undertaken, caution is recommended when CBD or THC is co-administered with drugs that are P-gp substrates, including NTI drugs, such as digoxin<sup>9</sup>.

### **Protein binding**

THC is highly bound to plasma proteins and might displace and increase the free fraction of other concomitantly administered protein-bound drugs. Although this displacement has not been confirmed in vivo, monitor patients for increased adverse reactions to NTI drugs that are highly protein-bound (e.g. warfarin, ciclosporin, amphotericin B) when initiating treatment or increasing the dosage of THC. This may be relevant when blood concentrations are being interpreted; care is needed as although the total drug may be changed, the free fraction may be stable<sup>11</sup>.

## **Clinical reports of pharmacokinetic drug-drug interactions**

### **Antiepileptic drugs (AED)**

In patients administered clobazam in combination with CBD, increased active metabolite N-desmethyloclobazam (nCLB) concentrations were observed<sup>30,31</sup>. This is likely due to CYP2C19 inhibition by CBD<sup>32</sup>. Higher nCLB concentrations were associated with a higher frequency of reports of sedation. Increased concentrations within normal therapeutic ranges of rufinamide, topiramate and zonisamide were reported in an open label safety study of CBD<sup>30</sup>. A small increase in stiripentol concentration has been reported when combined with CBD. The combination of CBD and valproate has been reported to cause elevations in liver function tests<sup>33,34</sup>. Although there was a 25% to 32% increase in 7-COOH-CBD exposure, the mechanism may not be completely pharmacokinetic. The results of a systematic chart review of a paediatric cohort suggest that monitoring for thrombocytopenia should be considered when valproate and CBD are combined<sup>35</sup>. Clinical and therapeutic drug monitoring (where applicable) is recommended with the use of CBD and AED.

Phenytoin is largely metabolised by CYP2C9 which has been shown to be inhibited by CBD in in-vitro studies. While no clinical studies have formally investigated this potential interaction, increased exposure to phenytoin, which has a NTI, may occur and dose reduction should be considered<sup>10</sup>.

UGT enzymes, including UGT2B7 are involved in the metabolism of lamotrigine. In-vitro, inhibition of UGT2B7 by CBD has been observed. No clinical studies have formally investigated this potential interaction which could result in

elevated plasma lamotrigine concentration when it is co-administered with CBD<sup>10</sup>.

**Additive effects may occur when cannabinoids are co-administered with other medication.**

In a published case series, co-administration of CBD with brivaracetam resulted in increased plasma brivaracetam concentrations<sup>36</sup>.

### **Anticoagulant, antiplatelet and thrombolytic agents**

Case reports have noted elevated INR in patients taking warfarin following use of various cannabinoids and dose forms. A clinically significant interaction between CBD and warfarin via CYP2C9 inhibition is predicted<sup>37-42</sup>. Based on in vitro evidence, THC and CBD may inhibit platelet aggregation and may theoretically increase the bleeding risk when used with antiplatelets and anticoagulants<sup>43</sup>. There has also been a case report of cerebral haemorrhage following administration of recombinant tissue plasminogen activator for ischaemic stroke in a patient with heavy cannabis use<sup>44</sup>.

### **Immunosuppressants**

A paediatric case report of increased everolimus concentration with CBD<sup>45</sup> is consistent with the results of a retrospective review, where increased mTOR inhibitor (everolimus and sirolimus) concentrations were observed in 19 of 25 patients taking CBD. However, coadministration of other drugs (including clobazam) that interact with CYP enzymes may have confounded the observed outcomes in some of the patients<sup>46</sup>.

Altered tacrolimus concentrations have been described in case reports and/or series when combined with CBD only or predominant products<sup>47,48</sup> and THC containing products<sup>49,50</sup>, although a large degree of intra-individual variability with the NTI drug tacrolimus limits the interpretation of these observations. Everolimus has been proposed to interact via CYP3A4<sup>45</sup> and tacrolimus via CYP3A and/or P-gp<sup>8,50</sup>. Concentration monitoring is advised and dose reduction may be required. Independent effects of cannabis medicines on the immune system also need to be considered.

### **Psychotropic drugs and theophylline**

The estimated clearance of chlorpromazine was faster in regular users of tobacco, cannabis and the combination than in non-users<sup>27</sup>.

A potential drug-drug interaction between CBD and lithium was highlighted in a case report. An elevated lithium concentration was observed<sup>51</sup>.

Increased clearance of theophylline has been observed with regular smoking of cannabis (> twice per week) with no effect observed with occasional use. The increased clearance is postulated to be caused by aromatic hydrocarbons produced by pyrolysis<sup>52</sup>.

### **Analgesics**

Raised methadone concentrations and increased sleepiness and fatigue were reported with concomitant use of methadone and CBD in a paediatric case report<sup>53</sup>. CYP2B6 plays a major role in methadone metabolism and CBD is reported in an in-vitro study to be an inhibitor of this enzyme.

A retrospective study in patients receiving buprenorphine as opioid maintenance therapy observed that cannabis use decreased the formation of norbuprenorphine and elevated buprenorphine concentrations, probably by inhibition of CYP3A4. This may result in enhanced or altered opioid activity and risk of intoxication<sup>54</sup>.

## **Pharmacodynamic drug interactions**

While pharmacokinetic drug interactions are more easily detected due to changes in measured plasma drug concentrations, identifying pharmacodynamic interactions with cannabis medicines is much more complex. Identifying the mechanism of interaction may also be complicated by the possibility of both pharmacokinetic and pharmacodynamic interactions occurring concurrently.

### **Sedation**

Cannabis has significant pharmacodynamic effects including sedation and cognitive impairment and these can be potentiated when co-administered with medications with similar effects or biological targets<sup>55</sup>.

Care should be taken when cannabinoids are co-administered with central nervous system depressants including hypnotics, sedatives and drugs with potential sedating effects as there may be an additive effect on sedation and muscle relaxing effects. This group includes commonly used drugs such as opioid, benzodiazepine, anticholinergic and antihistamine therapies.

### **Alcohol**

Studies evaluating the interaction of alcohol and cannabis have been conducted, with some reporting pharmacokinetic effects and other studies have reported conflicting results with some studies reporting no significant effect of alcohol on the pharmacokinetics of THC and others reporting significant increases in THC, CBD and metabolite levels. Pharmacodynamic studies reported psychomotor performance impairment when THC and alcohol were used concomitantly<sup>56</sup>.

### **Cannabinoids and opioids**

Several studies have reported that cannabis enhanced the analgesic effects of opioids, enabling lower opioid dosing. Vaporised cannabis administered to patients with chronic pain on opioid therapy was observed to increase analgesic effect with no significant differences in observed mean plasma opioid concentrations, suggesting this is a pharmacodynamic interaction. However, opioid delivery to the brain is influenced by ATP-binding cassette transporters and a pharmacokinetic interaction cannot be excluded<sup>24</sup>.

A systematic review on the opioid sparing effect of cannabinoids reported that pre-clinical studies provided robust evidence of the opioid sparing effects of cannabinoids while only one of the nine clinical studies identified provided very low-quality evidence of this effect. The authors concluded that prospective high-quality clinical trials were required to determine the opioid sparing effect of cannabinoids<sup>57</sup>.

A recent review of the therapeutic potential of opioid/cannabinoid combinations in humans noted that, while there is a groundswell of public advocacy supporting using cannabis and cannabinoids to replace opioid analgesics and to reduce the use of opioids, the current controlled clinical data does not support these uses when treating opioid use disorder or chronic pain<sup>58</sup>.

### **Cardiovascular effects**

Acute use of smoked THC can increase cardiac output, induce tachycardia, produce peripheral vasodilation, orthostatic hypotension and alter platelet aggregation. The tachycardic effect is presumed to be based on vagal inhibition and can be attenuated by beta blockers. With continued use, tolerance can develop to orthostatic hypotension and increased heart rate replaced by normal or slowed heart rate. Tolerance is mainly attributed to pharmacodynamic changes possibly due to receptor downregulation and/or desensitisation<sup>59</sup>. CBD may reduce heart rate and blood pressure<sup>60</sup>.



Haemodynamic monitoring is advised following cannabis medicine initiation and dose titration, particularly when combined with medications with similar cardiac or blood pressure altering effects. Cannabinoids may have a bidirectional effect on blood pressure and may also cause hypotension.

Cannabinoids may interact with drugs that act on the heart and circulation. These drugs include amphetamines, adrenaline, atropine, beta blockers and antidepressants. Additive tachycardia may occur when cannabinoids and atropine are taken together<sup>69</sup>.

Tachycardia has been described in case reports and series when tricyclic antidepressants were coadministered with smoked cannabis\* <sup>11,65-68</sup>.

Acute coronary syndrome (ACS) has been observed in case reports involving concomitant use of sildenafil with smoked cannabis<sup>65-68</sup>. Cannabis inhibition of sildenafil metabolism by CYP3A4 may have played a role<sup>67</sup>. Another case report highlighted the adverse haemodynamic effects of cannabis due to its effect on the sympathetic and parasympathetic nervous system, the effect of cannabis smoking on elevating carboxyhaemoglobin and the resulting increased oxygen demand not being met, which may lead to plaque rupture. It was also noted that since ACS has been reported in the presence of normal coronary arteries, coronary vasospasm may be a mechanism. Reduced blood pressure produced by sildenafil may also contribute to these symptoms<sup>66,68</sup>.

## Neuro-psychiatric effects

Case reports have described hypomania and/or mania in patients taking disulfiram, following use of smoked cannabis<sup>69,70</sup>. The alcohol content of some cannabis medicine dose forms may also precipitate disulfiram reactions<sup>12</sup>.

A patient developed mania following the combination of fluoxetine and smoked cannabis<sup>71</sup>.

THC may induce a transient increase in psychomimetic symptoms measured using the positive scale of the Positive and Negative Syndrome Scale (PANSS). In healthy volunteers who reported psychomimetic effects following inhaled (vaporised) THC, olanzapine was reported to reduce the effects of THC on the positive subscale. Haloperidol has also been reported to reduce psychomimetic effects<sup>72</sup>.

Pre-treatment of fifteen occasional cannabis users with the cholinesterase inhibitor rivastigmine was observed to attenuate

the effect of THC on cannabis-induced impairment of verbal memory<sup>73</sup>.

## Musculoskeletal

Care should be taken when co-administering Sativex® with antispasticity agents, since a reduction in muscle tone and power may occur, leading to a greater risk of falls<sup>9</sup>.

## Cancer immunotherapies

Cancer immunotherapies such as programmed cell death protein-1 (PD-1), programmed death-ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors are now used in a variety of different malignancies<sup>74</sup>. Evidence regarding their potential interactions with cannabis medicine products is limited but biologically plausible. A small retrospective observational trial performed in 2019 suggests that medicinal cannabinoids may reduce the response rate of non-small cell lung cancer patients to the PD-1 inhibitor nivolumab<sup>75</sup>. This is supported by a small prospective observational study in

2020 showing that medical cannabinoids may reduce progression free survival and overall survival of Stage 4 cancers treated with checkpoint inhibitors<sup>76</sup>. Given the small size of these studies their results should be interpreted with caution, and decisions regarding the use of cannabis medicines in patients on immunotherapies should be made on a case-by-case basis.

\*Smoking is not recommended as a route of administration in Australia due to the harmful effects of smoking.

## Monitoring outcomes

Monitoring should initially involve reviewing the patient weekly in person, and via phone if required in the interim between clinical reviews.

There are three areas of outcomes that should be considered:

### 1. Symptom control

A pre-defined measure of success should be negotiated with the patient prior to commencement of therapy. This can be measured by using a validated tool, for example by the Palliative Care Symptom Assessment Scale<sup>77</sup>.

### 2. Drug adverse events

Careful monitoring of patients for adverse events and the need for a change in dosage is important. Adverse events may become apparent after commencement or after change in dose. Adverse events may be related to

### Dosing in general:

- Start at low dose and frequency.
- Titrate to effect whilst monitoring for side effects.
- Patient response to these medications varies widely.
- Favour lower doses in older patients who may be at higher risk of CNS and cardiac adverse effects.

**The following is an example only – doses should be individualised for patient and indication. Dosing advice can only be provided on THC-based cannabis medicines. Information on the use of other medicinal cannabinoids (other than THC) cannot be provided at this stage due to limited evidence in the literature.**

Example for THC – adapted from Dronabinol (Marinol®)<sup>11</sup> Product Information (for treatment of anorexia):

- Starting dose 2.5 mg once daily or BD.
- Monitor for side effects.
- In view of likely multiple medications already prescribed and likelihood that the patient is older there is the potential for multiple drug interactions and side effects.
- In light of current evidence, generally there should be a maximum dose of 30 mg of THC per day. Beyond this dose, the risk of adverse effects may increase.

Example for THC:CBD – from Sativex®<sup>9</sup> oro-mucosal spray Product Information. Note that this Product Information was developed for the indication of spasticity in multiple sclerosis:

- Initially one spray per day, slow titration over two weeks.
- The mean number of sprays required for symptom relief was 4.81 per day (i.e. THC 12.5 mg/CBD 12.98 mg in divided doses daily).



other concurrent medications. Doses of these medicines should be adjusted as appropriate. Significant adverse events observed with unregistered medicines must be reported to the TGA (including dependence and withdrawal symptoms). Although some of the adverse events are well known (e.g. psychosis, anxiety) it is still important to notify the TGA when these events occur to enable patterns of toxicity and contributing factors to be elucidated, to support future prescribing information.

### 3. Pathology monitoring

Monitoring is generally only indicated when medications have specific characteristics (e.g. a NTI), where there is an established therapeutic range, where the consequences of undertreatment cannot be recognised clinically and can be serious (e.g. seizure) and/or if toxicity is suspected. CBD may cause hepatocellular injury. Patient's liver function biochemistry should be monitored prior to initiation and periodically as clinically indicated.

## Cessation and withdrawal

The cessation of long-term (of more than several months) use of THC based medicines may be associated with the experience of discontinuation effects. These can be categorised as relapse and/or withdrawal effects

Relapse refers to a worsening of the underlying condition (e.g. anorexia-cachexia) for which THC is being prescribed.

The cessation of heavy (e.g. daily or almost daily) and prolonged (of several months or more) cannabis use can be associated with a withdrawal syndrome in up to 15 to 40% of long-term cannabis users<sup>78,79</sup>. The features of cannabis withdrawal as defined in DSM-5 are shown in Table 3, with sleep problems (e.g. vivid dreams, insomnia), depressed mood and irritability/anxiety most commonly reported. Symptoms tend to emerge within 2-3 days of last THC use, peak within 4 to 14 days, with some residual symptoms persisting for 2-6 weeks<sup>80</sup>.

For those looking to discontinue THC based medication, a gradual dose taper over 4 to 8 weeks is generally recommended to minimise the severity of cannabis withdrawal symptoms. There is no effective pharmacotherapy for managing cannabis withdrawal at this time, and supportive care is recommended. Consider a referral to Alcohol and Drug Service or Addiction Medicine specialist for patients experiencing difficulties with withdrawal.

It should be noted that there is no recognised withdrawal syndrome associated with cessation of CBD.

**Table 3. DSM-5 Diagnostic criteria for cannabis withdrawal syndrome<sup>81</sup>**

<b>Criterion A</b>	Cessation of cannabis use that has been heavy and prolonged
<b>Criterion B</b>	3 or more of the following seven symptoms develop within several days of Criterion A: 1. Irritability, anger or aggression 2. Nervousness or anxiety 3. Sleep difficulty (insomnia) 4. Decreased appetite or weight loss 5. Restlessness 6. Depressed mood 7. Physical symptoms causing significant discomfort from at least one of the following: stomach pain, shakiness/tremors, sweating, fever, chills, headache
<b>Criterion C</b>	The symptoms in Criterion B cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
<b>Criterion D</b>	The symptoms are not due to a general medical condition and are not better accounted for by another disorder

## Further information

- NSW-based medical practitioners can obtain further information and assistance with prescribing tailored to the patient-specific clinical context from the [NSW Cannabis Medicines Advisory Service](#). The service can be contacted via email [HNELHD-CMAS@health.nsw.gov.au](mailto:HNELHD-CMAS@health.nsw.gov.au).
- Information on the NSW Prescribing Pathways for unregistered cannabis medicines is available from the NSW Government's [Centre for Medicinal Cannabis Research and Innovation](#).
- Information on NSW-based regulatory requirements around applying for and supplying Schedule 8 cannabis medicines, including requirements of the prescriber, dispensing and storage is available from the NSW Government's [Pharmaceutical Services](#) page on Cannabis Medicines.

## References

1. Department of Health Therapeutic Goods Administration. Guidance for the use of medicinal cannabis in the treatment of palliative care patients in Australia. 2017. <https://www.tga.gov.au/publication/guidance-use-medicinal-cannabis-treatment-palliative-care-patients-australia> (accessed 1 May 2021).
2. Caresearch – the Palliative Care Knowledge Network. <https://www.caresearch.com.au/caresearch/tabid/182/Default.aspx> (accessed 1 May 2021).
3. eTG Complete. Anorexia, weight loss and cachexia in palliative care. <https://www.tg.org.au/> (accessed 1 May 2021).
4. Roeland EJ, et al. Management of Cancer Cachexia: ASCO Guideline. *Journal of Clinical Oncology*. 2020;38(21):2438-2453.
5. Yavuzsen T, et al. Systematic review of the treatment of cancer associated anorexia and weight loss. *J Clin Oncol*. 2005;23(33):8500-11.
6. Transport for NSW Centre for Road Safety. <https://roadsafety.transport.nsw.gov.au/stayingsafe/alcoholdrug/drugdriving/index.html> (accessed 1 May 2021).
7. NSW Health Prescribed Cannabis Medicines and Fitness to Drive Factsheet.

- [https://www.medicinalcannabis.nsw.gov.au/\\_data/assets/pdf\\_file/0024/2868/Cannabis-and-Driving-Fact-Sheet-Patients-FINAL.pdf](https://www.medicinalcannabis.nsw.gov.au/_data/assets/pdf_file/0024/2868/Cannabis-and-Driving-Fact-Sheet-Patients-FINAL.pdf) (accessed 1 May 2021).
8. Department of Health Therapeutic Goods Administration. Guidance for the use of medicinal cannabis in Australia: Patient information. 2017. <https://www.tga.gov.au/publication/guidance-use-medicinal-cannabis-australia-patient-information> (accessed 1 May 2021).
  9. Sativex Product Information. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-01866-1> (accessed 1 May 2021).
  10. Epidyolex Product Information. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-PI-02648-1> (accessed 1 May 2021).
  11. Marinol Product Information. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/018651s029lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf) (accessed 1 May 2021).
  12. Syndros Product Information. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/205525s003lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205525s003lbl.pdf) (accessed 1 May 2021).
  13. Cesamet Product Information. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2006/018677s011lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf) (accessed 1 May 2021).
  14. Mucke M, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. *J Cachexia Sarcopenia Muscle*. 2018;9(2):220-234. doi: 10.1002/jcsm.12273
  15. Jatoi A, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *J Clin Oncol*. 2002;20(2):567-73. doi: 10.1200/JCO.2002.20.2.567.
  16. Turcott JG, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: A randomized, double-blind clinical trial. *Support Care Cancer*. 2018;26(9):3029-3038. doi: 10.1007/s00520-018-4154-9.
  17. Advani SM, et al. Pharmacological management of cachexia in adult cancer patients: Systematic review of clinical trials. *BMC Cancer*. 2018;18(1):1174. doi: 10.1186/s12885-018-5080-4.
  18. Department of Health Therapeutic Goods Administration. Guidance for the use of medicinal cannabis in Australia: Overview. 2017. <https://www.tga.gov.au/publication/guidance-use-medicinal-cannabis-australia-overview> (accessed 1 May 2021).
  19. Stout SM, et al. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. *Drug Metab Rev*. 2014;46(1):86-95. doi: 10.3109/03602532.2013.849268.
  20. Sachse-Seeboth C, et al. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. *Clin Pharmacol Ther*. 2009;85(3):273-6. doi: 10.1038/clpt.2008.213.
  21. Jiang R, et al. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. *Life Sci*. 2011;89(5-6):165-70. doi: 10.1016/j.lfs.2011.05.018.
  22. Silva DA, et al. Phytocannabinoid drug-drug interactions and their clinical implications. *Pharmacol Ther*. 2020;215:107621. doi: 10.1016/j.pharmthera.2020.107621.
  23. Stott CG, et al. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. *Eur J Clin Pharmacol*. 2013;69(5):1135-47. doi: 10.1007/s00228-012-1441-0.
  24. Vázquez M, et al. Potential pharmacokinetic drug-drug interactions between cannabinoids and drugs used for chronic pain. *Biomed Res Int*. 2020;2020:3902740. doi: 10.1155/2020/3902740.
  25. Qian Y, et al. The potential for pharmacokinetic interactions between cannabis products and conventional medications. *J Clin Psychopharmacol*. 2019;39(5):462-471. doi: 10.1097/JCP.0000000000001089.
  26. Brown JD, et al. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. *J Clin Med*. 2019;8(7):989. doi: 10.3390/jcm8070989.
  27. Anderson GD, et al. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. *Clin Pharmacokinet*. 2016;55(11):1353-1368. doi: 10.1007/s40262-016-0400-9.
  28. Zhu HJ, et al. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. *J Pharmacol Exp Ther*. 2006;317(2):850-7. doi: 10.1124/jpet.105.098541.
  29. Brzozowska NI, et al. The differential binding of antipsychotic drugs to the ABC transporter p-glycoprotein predicts cannabinoid-antipsychotic drug interactions. *Neuropsychopharmacology*. 2017;42(11):2222-2231. doi: 10.1038/npp.2017.50.
  30. Gaston TE, et al. Interactions between cannabidiol and commonly used antiepileptic drugs. *Epilepsia*. 2017;58(9):1586-1592. doi: 10.1111/epi.13852.
  31. VanLandingham KE, et al. A phase 2, double-blind, placebo-controlled trial to investigate potential drug-drug interactions between cannabidiol and clobazam. *J Clin Pharmacol*. 2020;60(10):1304-1313. doi: 10.1002/jcph.1634.
  32. Geffrey AL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. *Epilepsia*. 2015;56(8):1246-51. doi: 10.1111/epi.13060.
  33. Ben-Menachem E, et al. A phase II randomized trial to explore the potential for pharmacokinetic drug-drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy. *CNS Drugs*. 2020;34(6):661-672. doi: 10.1007/s40263-020-00726-4.
  34. Morrison G, et al. A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. *Clin Pharmacol Drug Dev*. 2019;8(8):1009-1031. doi: 10.1002/cpdd.665.
  35. McNamara NA, et al. Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid. *Epilepsia*. 2020;61(8):e85-e89. doi: 10.1111/epi.16596.
  36. Klotz KA, et al. Effects of cannabidiol on brivaracetam plasma levels. *Epilepsia*. 2019;60(7):e74-e77. doi: 10.1111/epi.16071.
  37. Damkier P, et al. Interaction between warfarin and cannabis. *Basic Clin Pharmacol Toxicol*. 2019;124(1):28-31. doi: 10.1111/bcpt.13152.
  38. Hsu A, et al. Probable interaction between warfarin and inhaled and oral administration of cannabis. *J Pharm Pract*. 2020;33(6):915-918. doi: 10.1177/0897190019854958.
  39. Yamreudeewong W, et al. Probable interaction between warfarin and marijuana smoking. *Ann Pharmacother*. 2009;43(7):1347-53. doi: 10.1345/aph.1M064.
  40. Grayson L, et al. An interaction between warfarin and cannabidiol, a case report. *Epilepsy Behav Case Rep*. 2017;9:10-11. doi: 10.1016/j.ebcr.2017.10.001.
  41. Brown GW, et al. Δ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR. *J Am Pharm Assoc* (2003). 2021;61(1):e57-e60. doi: 10.1016/j.japh.2020.07.028.
  42. Cortopassi J. Warfarin dose adjustment required after cannabidiol initiation and titration. *Am J Health Syst Pharm*. 2020;77(22):1846-1851. doi: 10.1093/ajhp/zxaa268.
  43. Greger J, et al. A review of cannabis and interactions with anticoagulant and antiplatelet agents. *J Clin Pharmacol*. 2020;60(4):432-438. doi: 10.1002/jcph.1557.
  44. Shere A, et al. Cannabis can augment thrombolytic properties of rtPA: Intracranial hemorrhage in a heavy cannabis user. *Am J Emerg Med*. 2017;35(12):1988.e1-1988.e2. doi: 10.1016/j.ajem.2017.09.049.
  45. Wiemer-Kruel A, et al. Cannabidiol interacts significantly with everolimus-report of a patient with tuberous sclerosis complex. *Neuropediatrics*. 2019;50(6):400-403. doi: 10.1055/s-0039-1695786.
  46. Ebrahimi-Fakhari D, et al. Cannabidiol elevates mechanistic target of rapamycin inhibitor levels in patients with tuberous sclerosis complex. *Pediatr Neurol*. 2020;105:59-61. doi: 10.1016/j.pediatrneurol.2019.11.017.
  47. Cuñetti L, et al. Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay. *Transplant Proc*. 2018;50(2):461-464. doi: 10.1016/j.transproceed.2017.12.042.
  48. Leino AD, et al. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. *Am J Transplant*. 2019;19(10):2944-2948. doi: 10.1111/ajt.15398.

49. Moadel D, et al. Medical marijuana-induced tacrolimus toxicity. *Psychosomatics*. 2019;60(6):603-605. doi: 10.1016/j.psych.2019.01.009.
50. Hauser N, et al. High on cannabis and calcineurin inhibitors: a word of warning in an era of legalized marijuana. *Case Rep Transplant*. 2016;2016:4028492. doi: 10.1155/2016/4028492.
51. Singh RK, et al. Drug-drug interactions between cannabidiol and lithium. *Child Neurol Open*. 2020;7:2329048X20947896. doi: 10.1177/2329048X20947896.
52. Rong C, et al. Drug-drug interactions as a result of co-administering  $\Delta^9$ -THC and CBD with other psychotropic agents. *Expert Opin Drug Saf*. 2018;17(1):51-54. doi: 10.1080/14740338.2017.1397128.
53. Madden K, et al. Clinically significant drug-drug interaction between methadone and cannabidiol. *Pediatrics*. 2020;145(6):e20193256. doi: 10.1542/peds.2019-3256.
54. Vierke C, et al. Buprenorphine-cannabis interaction in patients undergoing opioid maintenance therapy. *Eur Arch Psychiatry Clin Neurosci*. 2020 Jan 6. doi: 10.1007/s00406-019-01091-0.
55. Brown JD. Potential adverse drug events with tetrahydrocannabinol (THC) due to drug-drug interactions. *J Clin Med*. 2020;9(4):919. doi: 10.3390/jcm9040919.
56. Arellano AL, et al. Neuropsychiatric and general interactions of natural and synthetic cannabinoids with drugs of abuse and medicines. *CNS Neurol Disord Drug Targets*. 2017;16(5):554-566. doi: 10.2174/1871527316666170413104516.
57. Nielsen S, et al. Opioid-sparing effect of cannabinoids: A systematic review and meta-analysis. *Neuropsychopharmacology*. 2017;42(9):1752-1765. doi: 10.1038/npp.2017.51.
58. Babalonis S, et al. Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence. *Eur Neuropsychopharmacol*. 2020;36:206-216. doi: 10.1016/j.euroneuro.2020.03.002.
59. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet*. 2003;42(4):327-60. doi: 10.2165/00003088-200342040-00003.
60. Page RL, et al. Medical marijuana, recreational cannabis, and cardiovascular health: A scientific statement from the American Heart Association. *Circulation*. 2020;142(10):e131-e152. doi: 10.1161/CIR.0000000000000883.
61. Wilens TE, et al. Case study: Adverse effects of smoking marijuana while receiving tricyclic antidepressants. *J Am Acad Child Adolesc Psychiatry*. 1997;36(1):45-8. doi: 10.1097/00004583-199701000-00016.
62. Kizer KW. Possible interaction of TCA and marijuana. *Ann Emerg Med*. 1980;9(8):444. doi: 10.1016/s0196-0644(80)80163-6.
63. Hillard JR, et al. Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline. *Am J Psychiatry*. 1983;140(5):626-7. doi: 10.1176/ajp.140.5.626.
64. Mannion V. Case report: Adverse effects of taking tricyclic antidepressants and smoking marijuana. *Can Fam Physician*. 1999;45:2683-4.
65. Caldicott DG, et al. Keep off the grass: Marijuana use and acute cardiovascular events. *Eur J Emerg Med*. 2005;12(5):236-44. doi: 10.1097/00063110-200510000-00008.
66. Lee KB, et al. Cannabis smoking and sildenafil citrate induced acute coronary syndrome in a patient with myocardial bridge. *Anadolu Kardiyol Derg*. 2013;13(2):180-1. doi: 10.5152/akd.2013.045.
67. McLeod AL, et al. Myocardial infarction following the combined recreational use of Viagra and cannabis. *Clin Cardiol*. 2002;25(3):133-4. doi: 10.1002/clc.4960250310.
68. Arora S, et al. ST-segment elevation myocardial infarction in a 37-year-old man with normal coronaries--it is not always cocaine! *Am J Emerg Med*. 2012;30(9):2091.e3-5. doi: 10.1016/j.ajem.2011.12.033.
69. Lacoursiere RB, et al. Adverse interaction between disulfiram and marijuana: a case report. *Am J Psychiatry*. 1983;140(2):243-4. doi: 10.1176/ajp.140.2.243.
70. Mackie J, et al. Cannabis toxic psychosis while on disulfiram. *Br J Psychiatry*. 1994;164(3):421. doi: 10.1192/bjp.164.3.421a.
71. Stoll AL, et al. A case of mania as a result of fluoxetine-marijuana interaction. *J Clin Psychiatry*. 1991;52(6):280-1.
72. Kleinloog D, et al. Does olanzapine inhibit the psychomimetic effects of  $\Delta^9$ -tetrahydrocannabinol? *J Psychopharmacol*. 2012;26(10):1307-16. doi: 10.1177/0269881112446534.
73. Theunissen EL, et al. Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. *Psychopharmacology (Berl)*. 2012;220(2):341-50. doi: 10.1007/s00213-011-2479-x.
74. Esfahani K, et al. A review of cancer immunotherapy: from the past, to the present, to the future. *Curr Oncol*. 2020;27(Suppl 2):S87-S97. <https://doi.org/10.3747/co.27.5223>.
75. Taha T, et al. Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. *Oncologist*. 2019;24(4):549-554. doi: 10.1634/theoncologist.2018-0383.
76. Bar-Sela G, et al. Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. *Cancers (Basel)*. 2020;12(9):2447. doi: 10.3390/cancers12092447.
77. CareSearch Palliative Care Knowledge Network. Patient Assessment. <https://www.caresearch.com.au/caresearch/tabid/3389/Default.aspx> (accessed 1 May 2021).
78. Gorelick DA, et al. Diagnostic criteria for cannabis withdrawal syndrome. *Drug Alcohol Depend*. 2011;123(1-3):141-147. doi:10.1016/j.drugalcdep.2011.11.007.
79. Lintzeris N, et al. Findings from the Cannabis as Medicine Survey (CAMS-16): an online survey of medical cannabis use in Australia. *MJA*. 2018;209(5):211-216. doi: 10.5694/mja17.01247.
80. Hesse M, et al. Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers. *BMC Psychiatry*. 2013;13:258. <https://doi.org/10.1186/1471-244X-13-258>.
81. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). 2013. Arlington, VA.